Individual patents are often particularly valuable in the pharmaceuticals sector. After all, the patents relate to a precious commodity: our health. Behind each property right there are often huge investments as well as numerous jobs and research and sales organizations. This means that pharmaceutical companies should think carefully about who they entrust their patent to. Us, for example. At COHAUSZ & FLORACK, pharmaceuticals are always a partnership thing!
How do you protect your product from generics?
Pharmaceutical research companies that invest a great deal of R&D in their products face major challenges today. We, the COHAUSZ & FLORACK partners, represent your interests effectively, especially to competitors and generic manufacturers. Highly complex patent infringement proceedings are a standard part of our legal services. We are happy to support your company in any challenge the market throws at you!
In order to defend your intellectual property rights, especially against generic manufacturers, it is necessary to successfully defend oppositions to the grant of patents before the European Patent Office (EPO) and nullity actions before the German Federal Patent Court (BPatG) or the Unified Patent Court (UPC). Opposition proceedings are usually very complex and run in different countries simultaneously. This requires a great deal of coordination and interdisciplinary collaboration. You can count on us: with unique expertise, excellent contacts, exceptional dedication and commitment to detail and an uncompromising will to win and a talent for developing winning strategies, we represent your interests effectively - especially against competitors and generics manufacturers.
We have everything you need from a strong partner to support you in the IP sector:
- exceptional expertise
- many years of experience
- strong identification with you and your product
- reliability
- trust
... and much more! We look forward to empowering your company and ensuring that it remains innovative in the long term!
UPC Update - The new CMS is online
On July 8, the UPC has launched the first phase of its new CMS-rollout. Starting with limited functional scope, the new CMS is set to become fully operational in September.
G 1/23: No “Enablement” Hurdle for Prior Art Products Put on the Market – EPO Clarifies Scope of Prior Art
Enlarged Board of Appeal confirms: Commercially available products are prior art, even if they are not fully analyzable or reproducible
How the EPO addresses public prior use in clinical trials and patentability obstacles for pharmaceutical inventions
This article explores how the European Patent Office (EPO) addresses public prior use in the context of clinical trials.
IP strategies for the second funding round
As you scale, investors are looking at more than the potential of your IP, says Mathias Karlhuber. They now want to know whether it can support future growth and withstand any attacks.